Spineway SA Stocks

0.15Last Updated 17.04.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

€ 151805.01208

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
0.15
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Spineway SA engages in the design, manufacture, and marketing of implants and surgical instruments for treating disorder of spinal column. The company offers ayers rock, an anterior cervical interbody fusion cage; blue mountain, an anterior cervical interbody fusion plate; mont blanc, a posterior thoracolumbar pedicle screws; mont blanc baby, a pediatric growing rod system; mont blanc 3d+, a coplanar alignment system; kili, an anterior lumbar interbody fusion cage; twin peaks plif bullet shaped posterior lumbar interbody fusion cages; twin peaks olif graft vascularization interbody fusion cages; twin peaks tlif transforaminal lumbar interbody fusion cages; and mont blanc mis, a mini-invasive thoracolumbar system. It also provides sonora, a biomaterial for bone regeneration. In addition, the company exports its products. Spineway SA was incorporated in 2005 and is headquartered in Ecully, France.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is undervalued on EV/EBITDA, und

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks